JG
TCRT icon

Joel Greenblatt’s Alaunos Therapeutics TCRT Stock Holding History

Joel Greenblatt’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-106
Closed -$68K – 1210
2019
Q3 		$68K Buy
106
+13
+14% +$10.3K ﹤0.01% 1059
2019
Q2 		$81K Buy
+93
New +$64K ﹤0.01% 1103
2016
Q3 		– Sell
-285
Closed -$235K – 1041
2016
Q2 		$235K Sell
285
-358
-56% -$390K ﹤0.01% 858
2016
Q1 		$715K Sell
643
-91
-12% -$93.1K 0.01% 702
2015
Q4 		$915K Buy
+734
New +$1.21M 0.01% 615
2015
Q2 		– Sell
-727
Closed -$1.18M – 1040
2015
Q1 		$1.18M Buy
+727
New +$1.08M 0.01% 575

Other funds holding TCRT

MP
MSD Partners New York $76.8M AUM 34.91% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Joel Greenblatt's TCRT Position: Q4 2019 in Review

Joel Greenblatt sold out of Alaunos Therapeutics (TCRT) in Q4 2019, closing a stake of 106 shares — an estimated $68K sold.

Joel Greenblatt first reported a position in TCRT in Q1 2015 and held it in 6 quarters. The position peaked at $1.18M in Q1 2015. 148 funds tracked by Wall St. Rank hold TCRT as of Q4 2019.

  • Joel Greenblatt reported no remaining Alaunos Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Joel Greenblatt sold 106 Alaunos Therapeutics shares in Q4 2019, an estimated $68K.
  • Joel Greenblatt first reported a position in Alaunos Therapeutics in Q1 2015 and held it in 6 quarters.
  • Joel Greenblatt's Alaunos Therapeutics position peaked at $1.18M in Q1 2015.
  • 148 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2019.

Based on Gotham Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.